Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-risk Myelodysplastic Syndrome”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00006251
What this trial is testing

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Who this might be right for
Acute Undifferentiated LeukemiaAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma+61 more
Fred Hutchinson Cancer Center 21
Early research (Phase 1)Study completedNCT01834248
What this trial is testing

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia+2 more
Roswell Park Cancer Institute 9
Large-scale testing (Phase 3)UnknownNCT00234143
What this trial is testing

Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
St. Bartholomew's Hospital 360
Testing effectiveness (Phase 2)Looking for participantsNCT03999723
What this trial is testing

Combining Active and Passive DNA Hypomethylation

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid LeukemiaChronic Myelomonocytic Leukemia
Kirsten Grønbæk 196
Large-scale testing (Phase 3)Study completedNCT01029262
What this trial is testing

Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

Who this might be right for
Anemia
Celgene 239
Early research (Phase 1)Study completedNCT03573310
What this trial is testing

JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Who this might be right for
NeoplasmsSolid Tumor, AdultNon-Hodgkin Lymphoma+1 more
Janssen Research & Development, LLC 114
Not applicableUnknownNCT02833493
What this trial is testing

Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload

Who this might be right for
Aplastic AnemiaDysmyelopoietic SyndromesIron Overload
Peking Union Medical College Hospital 80
Not applicableLooking for participantsNCT02269592
What this trial is testing

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Who this might be right for
Monoclonal Gammopathy of Undetermined Significance (MGUS)Myelodysplastic SyndromesHematological Malignancies+5 more
Dana-Farber Cancer Institute 10,000
Not applicableLooking for participantsNCT07763054
What this trial is testing

Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome+6 more
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine 30
Not applicableStudy completedNCT02279654
What this trial is testing

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Who this might be right for
Myelodysplastic Syndrome
Celgene 389
Testing effectiveness (Phase 2)Ended earlyNCT01379274
What this trial is testing

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

Who this might be right for
MDS
Rush University Medical Center 2
Testing effectiveness (Phase 2)Study completedNCT00040846
What this trial is testing

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+97 more
Fred Hutchinson Cancer Center 60
Post-approval studies (Phase 4)Active Not RecruitingNCT05891249
What this trial is testing

Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India

Who this might be right for
Anemia
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)Active Not RecruitingNCT02912208
What this trial is testing

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic SyndromesThrombocytopenia
Associazione Qol-one 174
Large-scale testing (Phase 3)Active Not RecruitingNCT00843882
What this trial is testing

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Who this might be right for
AnemiaChronic Myelomonocytic LeukemiaDe Novo Myelodysplastic Syndrome+1 more
National Cancer Institute (NCI) 247
Testing effectiveness (Phase 2)Ended earlyNCT01795924
What this trial is testing

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Biosuccess Biotech Co., Ltd. 13
Testing effectiveness (Phase 2)Study completedNCT00744536
What this trial is testing

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicAngiogenesis
Sunnybrook Health Sciences Centre 20
Testing effectiveness (Phase 2)Study completedNCT01081431
What this trial is testing

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q

Who this might be right for
Myelodysplastic Syndromes
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH 91
Testing effectiveness (Phase 2)Ended earlyNCT01191749
What this trial is testing

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 7
Testing effectiveness (Phase 2)UnknownNCT04997811
What this trial is testing

Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes (MDS)
Prof. Janet Dunn 120
Next Page